EULAR 2024 Conference: Insights and Analysis

The current therapeutic approach to Sjogren’s syndrome focuses on symptomatic relief and broad immunosuppression due to a lack of specific targets. Emerging drugs like tibulizumab and nipocalimab offer promise but require further efficacy validation, while iscalimab shows potential for improving disease activity, highlighting a need for targeted therapies and updated clinical guidelines.

Mepolizumab shows long-term safety and efficacy in treating eosinophilic granulomatosis with polyangiitis (EGPA). In a study of 118 Japanese patients over 4.2 years, 91% completed treatment. Mepolizumab reduced oral corticosteroid (OCS) use, with 36% of patients becoming OCS-free. Clinical symptoms, relapses, and EGPA-related hospitalizations decreased significantly. Propensity score matching confirmed improved 5-year survival rates, lower Birmingham Vasculitis Activity Scores, and reduced glucocorticoid doses, demonstrating enhanced long-term disease control and survival. These findings highlight mepolizumab's potential as a cornerstone therapy for EGPA, offering better disease management and improved patient outcomes.

TAK-279, a potent TYK2 inhibitor, showed clinical efficacy and safety in a Phase IIb trial for moderate-to-severe psoriasis. Involving 290 patients, it achieved a higher ACR 20 response rate at 15 mg and 30 mg compared to placebo, along with improved ACR 50 and PASI 75 responses. TAK-279 also demonstrated reductions in disease activity and favorable safety outcomes, making it a promising candidate for psoriatic arthritis treatment.